Member Info for Adastra

This is the 3rd if you look at comments accompanying t/u of 10th May, Interims on 8th Aug and today's t/u. The price already reflected a subdued outlook whilst today's t/u has caused a big oversell. Rationale will prevail in the coming days as analysts work out that profits in RoW are as predicted and the US will quickly recover.....unless as I expect, a value predator steps in at this nadir. Any offer would certainly have to be more than 50% higher than today and probably considerably more.

That looks reasonably good to me so I bought in at 97p this morning. Outlook should improve and interest rate cut plus potential predators at this level adds spice to the mix. The fall looks grossly overdone hence its looking decidedly oversold from here.

Having turned a nice profit on ONT its time to look at security as Autumn swings in and Legal and General is picking up some nice pension obligations from companies on my radar and pf. Looks solid with good assets so I'm in here.

I think it's time to take my 40% rise here from my initial positive comments and average around 101p as posted. I had hoped that expiry of IPO protection would stimulate predatory interest but am concerned that any such move has now been diverted by the lawsuit pending progress. Good luck to all holders.

Super time to keep tucking a few away before the wider community catches on. All the relevant info is out in the public domain for those who can add 2 and 2 and 2 and 2. Perfect little under-the-radar gem.

With a £400m cash reserve and smooth runway to profit, the 58% margins are a compelling reason to invest with lots of scope to surprise on the upside.

Most relevant - ). The Group is in discussion with the FCA and will formally apply for admission to the ESCC segment by the end of 2024, subject to meeting the required eligibility criteria. The step up to the ESCC segment would make Oxford Nanopore eligible for FTSE indexation.

Consolidation phase should now be closing. The interims on Tuesday should give fresh impetus to Oxford Nanoparticle. The fact that the company has a secure cash runway to profitability with significant escalation thereafter is paramount. Both BioMerieux (7%) and Novo (5%+) have invested after considerable due diligence. Check the recent Novo Holdings posts on their reasons for wanting a holding with desire to increase it. September is the final month before the 3-year antitakeover protection ends. [It was built into the 2021 IPO as the CEO noted the extreme vulnerability of the tech to predators]. This also allows the process of lining up Oxford Nano into official LSE classification and categorization- it will certainly be allocated a future FTSE 250 place. This means that FTSE tracking funds will need to include ONT in their portfolios.

Logically, with no future funding requirements through to profit, two supportive big pharmas on the register, expiry of anti-takeover protection and pathfinder technology, it looks to be in a sweet spot.

I suspect that will be the next RNS to follow shortly, reinforcing buying sentiment. Should react strongly once these stale sellers are out of the way.

I'd be surprised if, come Sptember, the price doesn't start to rise to reflect expiry of anti-takeover protection on Oct 5th. Illumina has not shown its hand but it would be a sensible observation to assume that they are watching closely.

With one week to the interims and 5 weeks to expiry of 3yr inbuilt takeover protection this is too cheap. Big pharmas Novo and BioMerieux have holdings of 5 and 7% respectively and Novo has expressed a desire to increase. At this level, expect a sharp upward correction as that buying kicks in near term. Solid share.

This RNS will light up Cobra to the wider research/recommendation journalists - probably over the weekend and IC will certainly back up the positives here. All in all, these exceptional recovery rates are bound to increase coverage and also alert bigger players. The MCap is ridiculously low for the potential here.

Also of great importance for rapid adoption are the simple facts. Confined aquifer, saline and unused. • Permeable sands within mineralised zones. Rare earth mineralisation concentrated within three zones. Lends itself ideally to a recirculatory extraction system.

Look at those results and then look at the MCap having carried out all your research.....and pat yourself on the back. This is only going one way....and it's not down methinks.

"High recoveries from high grade ore coupled with low acid consumption and low cost ISR mining are standout factors for the Boland Project. We are defining a scalable, high grade ionic rare earth project whose unique geology supports an ISR process, a point of difference to conventional ionic REE projects.

These metallurgy results indicate that improved recoveries can be achieved through further optimising the lixiviant used in the ISR process. By achieving high recoveries with low impurities and at low levels of acid consumption we expect to optimise metallurgical and cost parameters for the in situ recovery of REEs.

China may have the 3Ms. Cobra and Australia have the 3V's.

Very stable government, Vast REE resources, Very easy to extract. Watch this space.

Wall Street Journal 25st August

Rare-Earth Minerals Are the Ace Up Beijing’s Sleeve

The U.S. remains asleep at the wheel.

“A 3 a.m. wake-up call for Washington came last week when China announced export restrictions on antimony, a critical mineral in weapon systems and semiconductors.” Yet China’s move shouldn’t surprise.

With rare earths and critical materials, Beijing has an ace up its sleeve. As Deng Xiaoping stressed in 1992, “The Middle East has oil; China has rare earths.” China intends to use its dominant position in the “3Ms”: mining, metallurgy and materials science.

Final shout from the rooftops to check this out.

Look where it is, look what it has and look at the value.

You can only kick yourself if you don't do the research here and reach the same conclusion. On all present data this looks ridiculously undervalued imo.

The more I research this share the more it looks ridiculously undervalued. It really is well worth the time spent doing your own research here. Look at the stable Australian jurisdiction, look at the quality of the assets and the proven minimally invasive extraction techniques that are already proven for U and REE. The only remaining hurdle which is already being vaulted is to prove up already bench-test excellent extraction percentages. Once that is confirmed in the near-term Cobra should rocket to reflect intrinsic value here. This share has gold, uranium and rare Earth's. The ease of access and extraction of REEs using leach technology is the cheapest available giving huge upside given China's dominance in supplies.

Had been watching....but...Dilution and mCap down to £58m? Poor BoD timing which could have been much better handled. GL to holders but now not one for me. Will wait till Q1 25 and see.